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Background: The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation trial reported similar outcomes for stable angina 
patients randomized to optimal medical therapy (OMT) with or without percutaneous coronary intervention (PCI). The aim of this analysis was to 
examine differences in therapeutic outcome by baseline severity of stress myocardial ischemia.
Methods: A total of 1,388 of the 2,287 enrolled patients underwent pre-treatment stress myocardial perfusion SPECT. Site-Interpreted multiple 
vascular territories or ≥10% myocardium defined moderate-severe ischemia, which was present in 409 (29%). Cox proportional hazards models were 
used to estimate all-cause death (n=122).
Results: A first order interaction of randomized treatment by ischemia trended toward a benefit of improved survival with OMT+PCI versus OMT 
alone (p=0.079). In moderate-severe ischemia, the reduction in mortality with PCI+OMT was significant (hazard ratio [HR] 0.64, 95% CI=0.41-0.99, 
p=0.046). Cumulative survival in patients with moderate-severe ischemia was 69.5% for OMT+PCI as compared to 74.2% for OMT alone (p=0.073, 
Figure).
Conclusions: This prespecified subgroup analysis suggests that PCI may reduce mortality in patients with moderate-severe ischemia. 
These results require validation in a randomized clinical trial sufficiently powered in high risk patients with a significant ischemic burden.
